Skip to content

Welcome to Discover Pharma! Today is : October 16, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

urinary incontinence

  • Drug Discovery & Development

    Cyllene gene therapy for bladder disorder gains FDA RMAT designation

    Cyllene Therapeutics’ experimental gene therapy EG110A has received US FDA [...]

    September 16, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    EG 427 reports strong initial results for DNA therapy in neurogenic bladder trial

    EG 427 has released encouraging first clinical data from its [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Aravax to present Phase 2 peanut allergy data in November
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • CPHI Milan to focus on practical sustainability across pharma supply chains
    Categories: Manufacturing & Supply Chain, Opinion & Events
  • Brenntag and dsm-firmenich agree global GMP vitamin deal
    Categories: Clinical & Regulatory
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top